BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33370681)

  • 21. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
    Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
    Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
    Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
    Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
    He J; Chen XF; Xu MG; Zhao J
    Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
    Wang S; Yuan B; Wang Y; Li M; Liu X; Cao J; Li C; Hu J
    Int J Colorectal Dis; 2021 Jan; 36(1):117-130. PubMed ID: 32910207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
    Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.
    Xie Q; Wang L; Zheng S
    Dis Markers; 2020; 2020():1817931. PubMed ID: 32724483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
    Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G
    Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
    Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y
    Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
    Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
    Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
    Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
    Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
    [No Abstract]   [Full Text] [Related]  

  • 36. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
    Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma.
    Wotman M; Herman SW; Costantino P; Tham T
    Laryngoscope; 2020 Nov; 130(11):2598-2606. PubMed ID: 32112431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
    Zhao S; Qiu Z; He J; Li L; Li W
    Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
    Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
    Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.
    Karsono R; Azhar MA; Pratiwi Y; Saputra F; Nadliroh S; Aryandono T
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2069-2077. PubMed ID: 34319029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.